Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.86 +0.17 (+0.68%)
Streaming Delayed Price Updated: 3:12 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
ARPA-H Taps Former DARPA Innovator to Ignite High-Risk, High-Reward Health Tech Revolution
In a move poised to reshape the landscape of biomedical innovation, the United States government officially appointed Dr. Renee Wegrzyn, a distinguished former official from the Defense Advanced... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
Danaher Tops Its 5% Chase Zone As One Key Division Drives Growth
Shares surged Tuesday after the medical research company beat third-quarter forecasts on the back of its bioprocessing division. 
Via Investor's Business Daily
2 Mega-Dividend Stocks With Yields As High As 7%
Dividend stocks with high yields can be great investment opportunities, but those yields can also be red flags. 
Via The Motley Fool
Topics Economy Government Intellectual Property
Mark Cuban Isn't Convinced TrumpRx Is Going To 'Change The Game' But He's Giving Them 'Credit For Trying'
Billionaire entrepreneur Mark Cuban offered rare praise for the Trump administration's push to lower prescription drug costs, calling its TrumpRx initiative "a good start," while still acknowledging... 
Via Benzinga
Topics Government
2 Large-Cap Stocks with Exciting Potential and 1 We Avoid
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an... 
Via StockStory
Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche
The company took on Roche's Xolair in a 16-week study of patients with a chronic hives disorder. 
Via Investor's Business Daily
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
From Arvinas Inc.
Via GlobeNewswire
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
2 High-Yield Dividend Stocks Too Cheap to Ignore
They are both yielding above 5%. 
Via The Motley Fool
Topics Intellectual Property World Trade
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
From Pfizer Inc.
Via Business Wire
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
From Pfizer Inc.
Via Business Wire
Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients
Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with bladder cancer. 
Via Investor's Business Daily
Invo Fertility Stock Is Plunging After White House Announcement
INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible. 
Via Benzinga
Why Eli Lilly (LLY) Stock Is Down Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the company’s... 
Via StockStory
Topics Economy Government
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment
NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to daily oral medication. 
Via Benzinga
QSM Asset Management Dumps 36,000 Whirlpool (WHR) Shares in Q3 2025
Via The Motley Fool
Topics Regulatory Compliance
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer. 
Via Benzinga
Topics Government
Eli Lilly Makes A Bold Claim For Its Biggest Cancer Drug
Eli Lilly said Friday a combo using Verzenio cut the risk of death by nearly 16% over two years for breast cancer patients. 
Via Investor's Business Daily
ASSET PLANNING Exits Full Stake in Pfizer Worth $2.7 Million
Via The Motley Fool
Topics Regulatory Compliance
AI: The Medical Maverick – Navigating Hype and Hope in Healthcare’s Digital Revolution
Artificial intelligence (AI) stands at the precipice of a profound transformation in healthcare, promising a future where diagnostics are sharper, treatments are more personalized, and patient care is... 
Via TokenRing AI
Topics Artificial Intelligence
QSM Asset Management Takes $11.5 Million Stake in Rio Tinto, Expands Energy Exposure
Via The Motley Fool
Navigating the Currents: Volatility and Growth Define U.S. Markets Amidst AI Boom and Geopolitical Headwinds
As of October 16, 2025, the U.S. stock market is a tapestry woven with threads of robust corporate earnings, groundbreaking technological advancements, and persistent geopolitical and economic... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
QSM Asset Management Buys $6.8 Million of Pfizer Stock as Pharma Giant Lags Market
Via The Motley Fool
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years
It's the best time in a while to scoop up shares of this stock from the discount bin. 
Via The Motley Fool
Topics Intellectual Property World Trade
Why Moderna Might Be a One-Hit Wonder
Moderna's sales have plummeted in recent years along with diminishing demand for COVID vaccines. 
Via The Motley Fool
Dividend Duo Delights Investors: Meta Platforms and Johnson & Johnson Shine in 2025
In a year marked by evolving market dynamics and a persistent search for both growth and stability, two distinct titans of industry—Meta Platforms (NASDAQ: META) and Johnson & Johnson (NYSE: JNJ)—have... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Curious about the most active S&P500 stocks in today's session?
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Wednesday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
Wall Street's Earnings Momentum Fades, Market Dips Amidst Trade Tensions
Wall Street witnessed a significant shift this Wednesday as an eagerly anticipated earnings push ultimately petered out, sending stocks into the red. This downturn followed a volatile Tuesday, which... 
Via MarketMinute
Topics Economy Supply Chain World Trade
Pfizer CEO Reportedly Says Vaccine Approvals Getting Harder
According to a report from Bloomberg, Bourla said that it's harder to get vaccine approvals and not drug approvals. 
Via Stocktwits
Topics Government World Trade
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.